Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial

Gordon, J. N.; Trebble, T. M.; Ellis, R. D.; Duncan, H. D.; Johns, T.; Goggin, P. M.
April 2005
Gut;Apr2005, Vol. 54 Issue 4, p540
Academic Journal
Background: Proinflammatory cytokines, especially tumour necrosis Factor (TNF-α), play a prominent role in the pathogenesis of cancer cachexia. Thalidomide, which is an inhibitor of TNF-α synthesis, may represent a novel and rational approach to the treatment of cancer cachexia. Aims: To assess the safety and efficacy of thalidomide in attenuating weight loss in patients with cachexia secondary to advanced pancreatic cancer. Methods: Fifty patients with advanced pancreatic cancer who had lost at least 10% of their body weight were randomised to receive thalidomide 200 mg daily or placebo for 24 weeks in a single centre, double blind, randomised controlled trial. The primary outcome was change in weight and nutritional status. Results: Thirty three patients (16 control, 17 thalidomide) were evaluated at four weeks, and 20 patients (eight control, 12 thalidomide) at eight weeks. At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm3 in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p=0.005) and 4.46 cm3 (absolute difference -5.6 cm3 (95% CI -8.9 to -2.2); p=0.002) in the placebo group. At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm3 in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p=0.034) and 8.4 cm3 (absolute difference -7.9 cm3 (95% CI -14.0 to -1.8); P = 0.014) in the placebo group. Improvement in physical functioning correlated positively with weight gain (r= 0.56, p = 0.001). Conclusion: Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.


Related Articles

  • TNF-α in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility. Remco van Horssen // Oncologist;Apr2006, Vol. 11 Issue 4, p397 

    Tumor necrosis factor alpha (TNF-α), isolated 30 years ago, is a multifunctional cytokine playing a key role in apoptosis and cell survival as well as in inflammation and immunity. Although named for its antitumor properties, TNF has been implicated in a wide spectrum of other diseases. The...

  • Steering anti-cancer drugs away from the TRAIL. Nagata, Shigekazu // Nature Medicine;May2000, Vol. 6 Issue 5, p502 

    Reports on concerns about the side effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a cytokine which has been hyped as an almost magical drug for cancer treatment. Possible side effects in the liver; Death-domain-containing receptors of TRAIL; Decoy receptors for...

  • Cytokine anniversary: TNF trailblazers five centuries apart. Libert, Claude // Nature;7/9/2015, Vol. 523 Issue 7559, p158 

    A letter to the editor is presented concerning the 40th anniversary of a scientific paper that described the discovery of the cell-signalling protein known as tumour necrosis factor (TNF) in the inflammatory disease a cytokine.

  • TNF.  // Encyclopedic Reference of Molecular Pharmacology;2004, p911 

    An encyclopedia entry for "TNS" is presented, which refers to tumor necrosis factor.

  • Commentary: Systemic or regional chemotherapy: does it matter and should surgeons be involved? Stephens, F.O. // Journal of the Royal College of Surgeons of Edinburgh;Apr98, Vol. 43 Issue 2, p80 

    Comments on the use of tumor necrosis factor (TNF) as an immunological anti-cancer agent. Efficacy of the TNF in closed circuit perfusion techniques together with other anti-cancer agents; Treatment of multiple melanoma metastases; Difference of tumor response due to the use of regional...

  • cytokine storm.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p571 

    A definition of the term "cytokine storm" is presented, which refers to the massive release of interleukins, tumor necrosis factor alpha and other mediators of inflammation that also trigger bleeding, clotting or shock.

  • Suppressed Alloantigen Presentation, Increased TNF-α, IL-1, IL-1Ra, IL-10, and Modulation of TNF-R in UV-Irradiated Human Skin. Barr, Robert M.; Walker, Susan L.; Tsang, Wailin; Harrison, Graham I.; Ettehadi, Parisa; Greaves, Malcolm W.; Young, Antony R. // Journal of Investigative Dermatology;May99, Vol. 112 Issue 5, p692 

    Cytokines induced in skin by ultraviolet radiation cause local and systemic immunosuppression. Tumor necrosis factor α, interleukin-1, and interleukin-10 are key mediators in the mouse, but less is known about cytokine synthesis and function in ultraviolet-irradiated human skin. We exposed...

  • Cytokines and particle-induced inflammatory cell recruitment. Driscoll, Kevin E.; Carter, Janet M.; Hassenbein, Diana G.; Howard, Brian // Environmental Health Perspectives Supplements;Sep97 Supplement 5, Vol. 105, p1159 

    Summarizes some of the evidence indicating a key role for the cytokine tumor necrosis factor alpha (TNF-alpha) as well as members of the cytokine family in particle-induced inflammation in the lung. Background on tumor necrosis factor; Two branches of the chemokine family; Epithelial cells and...

  • Identification of NF-?B-regulated genes induced by TNFa utilizing expression profiling and RNA interference. Zhou, Anwu; Scoggin, Shane; Gaynor, Richard B; Williams, Noelle Sevilir // Oncogene;4/3/2003, Vol. 22 Issue 13, p2054 

    Tumor necrosis factor a (TNFa) is a proinflammatory cytokine with important roles in regulating inflammatory responses as well as cell cycle proliferation and apoptosis. Although TNFa stimulates apoptosis, it also activates the transcription factor NF-?B, and studies have shown that inhibition...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics